查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2028048

抗癌藥物市場規模、佔有率、成長和全球產業分析：按類型、應用和地區分類，並對 2026-2034 年進行洞察和預測。

Oncology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

抗癌藥物市場的成長要素

由於癌症負擔日益加重以及治療技術的不斷進步，全球抗癌藥物市場正經歷顯著成長。預計到2025年，該市場規模將達到2,564.6億美元，2026年將達到2,863.6億美元，到2034年將進一步擴大至6,975.9億美元，2026年至2034年間的複合年成長率將達到11.77%。

預計到2025年，北美將引領全球市場，佔45.44%的市場。這主要得益於高額的醫療保健支出、創新治療方法的快速普及以及強力的監管支持。

抗癌藥物是用於治療多種癌症（包括固體癌和骨髓惡性腫瘤）的處方藥。早期癌症治療的廣泛應用，以及生物標記檢測和診斷技術的進步，是推動市場成長的主要動力。

市場趨勢

抗癌藥物市場的關鍵趨勢之一是高價值標靶治療的早期應用。該行業正從治療晚期癌症轉向在疾病早期階段進行治療，從而提高存活率並降低復發風險。

此外，皮下製劑的研發正蓬勃發展。這些製劑能夠提高病患用藥的便利性，縮短住院時間，並提升治療效果，即使在競爭激烈的藥物領域，也能更快被市場接受。

另一個重要趨勢是對伴隨診斷的日益依賴。伴隨診斷能夠根據特定患者的情況制定個人化治療方案，並有助於改善臨床療效。

市場促進因素

癌症發生率上升和先進新藥的上市

全球癌症發生率的上升是主要的成長要素。吸菸、污染、生活方式改變和人口老化等因素都導致了癌症患者人數的增加。

同時，抗體藥物複合體（ADC）和分子標靶藥物等先進治療方法的出現顯著改善了治療效果。這些治療方法結合了精準標靶化和強大的腫瘤殺傷能力，從而改善了患者的預後。

聯合治療的廣泛應用

免疫療法與標靶治療相結合的聯合治療正在創造新的成長機會。這些治療方法透過提高緩解率和擴大適用患者群體，推動了市場擴張。

市場限制因素

儘管市場成長強勁，但由於治療成本飆升和報銷壓力，仍面臨許多挑戰。許多先進的抗癌藥物需要強力的臨床證據來證明其成本合理，這可能會延遲報銷核准。

此外，專業治療中心的普及程度有限以及嚴格的監管要求可能會限制創新治療方法的引入，尤其是在發展中地區。

市場挑戰

抗癌藥物市場面臨的主要挑戰之一是放射性藥物和抗體藥物複合體（ADC）等先進治療方法的生產過程複雜。這些治療方法需要專門的基礎設施、嚴格的操作條件和精確的物流系統。

此外，供應鏈限制和某些藥物保存期限短阻礙了藥物的廣泛普及，並影響了整體市場成長。

細分分析

藥物類別

標靶治療因其在癌症治療中的高效性和精準性而佔​​市場主導地位。這包括單株抗體和其他先進治療方法。細胞毒性藥物也因其廣泛應用而保持穩定成長。

透過治療方法

標靶治療在該領域佔領先地位，因為它能夠特異性攻擊癌細胞，同時最大限度地減少對健康組織的損傷。免疫療法有望快速發展，因為它能夠增強人體自身的免疫反應。

適應症

肺癌在全球發生率最高，因此佔最大的市場佔有率。由於人們對乳癌的認知不斷提高以及早期診斷的廣泛應用，預計乳癌也將顯著成長。

按劑型

注射劑藥物佔市場主導地位。這是因為大多數腫瘤治療都需要在醫療機構進行，以確保更高的療效和更完善的監測。

透過分銷管道

由於需要對癌症藥物進行專門的管理和監測，醫院藥房在市場上佔主導地位，並擁有最大的市場佔有率。

區域趨勢

  • 北美：在創新和強大的醫療保健基礎設施的支持下，它是最大的市場，預計到 2025 年將成長到 1087.9 億美元，到 2026 年將成長到 1184.1 億美元。
  • 歐洲：在報銷政策和先進治療方法的推動下，預計到 2025 年市場規模將達到 568.6 億美元，到 2026 年將達到 636.9 億美元。
  • 亞太地區：受中國和印度患者數量不斷增加的推動，該地區正在經歷快速成長，預計到 2025 年將達到 509.5 億美元，到 2026 年將達到 578.2 億美元。
  • 拉丁美洲、中東和非洲：這些新興市場由於醫療保健投資增加和意識提升而經歷穩步成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年區域和國家特定癌症盛行率
  • 概述各種抗癌藥物的核准情況及臨床試驗情形。
  • 主要品牌/公司價格分析，2025 年
  • 關鍵產業趨勢（併購、合作）

第5章：2021-2034年全球抗癌藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 細胞毒性藥物
      • 烷化劑
      • 抗代謝物
      • 其他
    • 標靶治療藥物
      • 單株抗體
      • 其他
    • 荷爾蒙藥物
    • 其他
  • 市場分析、洞察與預測：按療法分類。
    • 化療
    • 標靶治療
    • 免疫療法
    • 其他
  • 市場分析、洞察與預測：按指標
    • 肺癌
    • 胃癌
    • 結腸癌
    • 乳癌
    • 攝護腺癌
    • 其他
  • 市場分析、洞察與預測：按劑型分類
    • 固體的
      • 藥片
      • 膠囊
    • 液體
    • 注射藥物
      • 預填充式注射器
      • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美抗癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲抗癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區抗癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲抗癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲抗癌藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • F. Hoffmann-La Roche Ltd.
    • AbbVie, Inc.
    • Novartis AG
    • Pfizer Inc.
    • AstraZeneca
    • GSK plc
    • Eli Lilly and Company
    • Sanofi
    • Bayer AG
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
Product Code: FBI103431

Growth Factors of oncology drugs Market

The global oncology drugs market has witnessed substantial growth due to the rising burden of cancer and continuous advancements in treatment technologies. The market was valued at USD 256.46 billion in 2025 and is projected to reach USD 286.36 billion in 2026, further expanding to USD 697.59 billion by 2034, registering a robust CAGR of 11.77% during 2026-2034.

North America dominated the global market in 2025, accounting for 45.44% of the total share, driven by high healthcare spending, rapid adoption of innovative therapies, and strong regulatory support.

Oncology drugs are prescription medications used to treat various cancers, including solid tumors and hematological malignancies. Increasing adoption of early-stage cancer treatment, supported by advancements in biomarker testing and diagnostics, is significantly driving market growth.

Market Trends

One of the key trends shaping the oncology drugs market is the early use of high-value targeted therapies. The industry is shifting from treating advanced-stage cancers to addressing early-stage conditions, improving survival rates and reducing recurrence risks.

Additionally, the development of subcutaneous drug formulations is gaining traction. These formulations improve patient convenience, reduce hospital time, and enhance treatment efficiency, leading to faster adoption even in competitive drug categories.

Another important trend is the increasing reliance on companion diagnostics, which helps tailor treatments to specific patient profiles, improving clinical outcomes.

Market Drivers

Rising Cancer Burden and Advanced Drug Launches

The increasing prevalence of cancer worldwide is a major growth driver. Factors such as smoking, pollution, lifestyle changes, and aging populations contribute to the rising number of cancer cases.

Simultaneously, the launch of advanced therapies such as antibody-drug conjugates and targeted drugs has significantly improved treatment effectiveness. These therapies combine precision targeting with strong tumor-killing capabilities, enhancing patient outcomes.

Growing Adoption of Combination Therapies

Combination therapies, including immunotherapy with targeted drugs, are creating new growth opportunities. These treatments improve response rates and expand the eligible patient population, driving market expansion.

Market Restraints

Despite strong growth, the market faces challenges due to high treatment costs and reimbursement pressures. Many advanced oncology drugs require strong clinical evidence to justify their cost, leading to delays in reimbursement approvals.

Additionally, limited access to specialized treatment centers and strict regulatory requirements can restrict the adoption of innovative therapies, especially in developing regions.

Market Challenges

A significant challenge in the oncology drugs market is the complex manufacturing process of advanced therapies such as radiopharmaceuticals and antibody-drug conjugates. These treatments require specialized infrastructure, strict handling conditions, and precise logistics.

Supply chain constraints and short shelf-life of certain drugs also hinder widespread accessibility, impacting overall market growth.

Segmentation Analysis

By Drug Class

Targeted drugs dominate the market due to their high efficacy and precision in treating cancer. These include monoclonal antibodies and other advanced therapies. Cytotoxic drugs also continue to grow steadily due to their widespread use.

By Therapy

Targeted therapy leads the segment owing to its ability to specifically attack cancer cells while minimizing damage to healthy tissues. Immunotherapy is expected to grow rapidly due to its effectiveness in enhancing the body's immune response.

By Indication

Lung cancer holds the largest market share due to its high prevalence globally. Breast cancer is also expected to witness significant growth due to increasing awareness and early diagnosis.

By Dosage Form

Injectable drugs dominate the market, as most oncology treatments are administered in clinical settings for better efficacy and monitoring.

By Distribution Channel

Hospital pharmacies lead the market, accounting for the largest share due to the need for specialized administration and monitoring of oncology drugs.

Regional Insights

  • North America: Largest market with USD 108.79 billion in 2025, growing to USD 118.41 billion in 2026, driven by innovation and strong healthcare infrastructure.
  • Europe: Valued at USD 56.86 billion in 2025 and USD 63.69 billion in 2026, supported by reimbursement policies and advanced treatment adoption.
  • Asia Pacific: Rapidly growing region with USD 50.95 billion in 2025 and USD 57.82 billion in 2026, driven by rising patient population in China and India.
  • Latin America & Middle East & Africa: Emerging markets with steady growth due to increasing healthcare investment and patient awareness.

Competitive Landscape

The oncology drugs market is moderately fragmented, with major players focusing on innovation, acquisitions, and expanding product pipelines. Leading companies include Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb, Novartis, Pfizer, and Roche. These firms dominate due to their strong portfolios of blockbuster cancer drugs and continuous R&D investments.

Conclusion

The global oncology drugs market is poised for significant expansion, growing from USD 256.46 billion in 2025 to USD 697.59 billion by 2034. This growth is primarily driven by rising cancer prevalence, increasing adoption of targeted and combination therapies, and continuous innovation in drug development.

However, challenges such as high treatment costs, reimbursement barriers, and complex manufacturing processes remain critical concerns. Despite these hurdles, advancements in personalized medicine, early diagnosis, and novel therapeutic approaches are expected to reshape the market landscape.

Segmentation By Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region

By Drug Class * Cytotoxic Drugs

    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Others
  • Hormonal Drugs
  • Others

By Therapy * Chemotherapy

  • Targeted Therapy
  • Immunotherapy
  • Others

By Indication * Lung Cancer

  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others

By Dosage Form * Solid

    • Tablets
    • Capsules
  • Liquid
  • Injectable
    • Prefilled Syringes
    • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)

    • U.S. (By Drug Class)
    • Canada (By Drug Class)
  • Europe (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • U.K. (By Drug Class)
    • Germany (By Drug Class)
    • France (By Drug Class)
    • Italy (By Drug Class)
    • Spain (By Drug Class)
    • Scandinavia (By Drug Class)
    • Rest of Europe (By Drug Class)
  • Asia Pacific (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • Japan (By Drug Class)
    • China (By Drug Class)
    • India (By Drug Class)
    • Australia (By Drug Class)
    • Southeast Asia (By Drug Class)
    • Rest of Asia Pacific (By Drug Class)
  • Latin America (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • Brazil (By Drug Class)
    • Mexico (By Drug Class)
    • Rest of Latin America (By Drug Class)
  • Middle East & Africa (By Drug Class, By Drug Class, By Therapy, By Indication, By Dosage Form, By Distribution Channel, By Country/Sub-Region)
    • South Africa (By Drug Class)
    • GCC (By Drug Class)
    • Rest of the Middle East & Africa (By Drug Class)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cancer, By Region/Country, 2025
  • 4.2. Overview of Different Oncology Drugs With Respect to Regulatory Approvals and Clinical Trials
  • 4.3. Pricing Analysis, Key Brands / Key Players, 2025
  • 4.4. Key Industry Development (Mergers, Acquisitions and Partnerships)

5. Global Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Cytotoxic Drugs
      • 5.1.1.1. Alkylating Agents
      • 5.1.1.2. Antimetabolites
      • 5.1.1.3. Others
    • 5.1.2. Targeted Drugs
      • 5.1.2.1. Monoclonal Antibodies
      • 5.1.2.2. Others
    • 5.1.3. Hormonal Drugs
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Immunotherapy
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Lung Cancer
    • 5.3.2. Stomach Cancer
    • 5.3.3. Colorectal Cancer
    • 5.3.4. Breast Cancer
    • 5.3.5. Prostate Cancer
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.4.1. Solid
      • 5.4.1.1. Tablets
      • 5.4.1.2. Capsules
    • 5.4.2. Liquid
    • 5.4.3. Injectable
      • 5.4.3.1. Prefilled Syringes
      • 5.4.3.2. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - By Geography
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Cytotoxic Drugs
      • 6.1.1.1. Alkylating Agents
      • 6.1.1.2. Antimetabolites
      • 6.1.1.3. Others
    • 6.1.2. Targeted Drugs
      • 6.1.2.1. Monoclonal Antibodies
      • 6.1.2.2. Others
    • 6.1.3. Hormonal Drugs
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Therapy
    • 6.2.1. Chemotherapy
    • 6.2.2. Targeted Therapy
    • 6.2.3. Immunotherapy
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Lung Cancer
    • 6.3.2. Stomach Cancer
    • 6.3.3. Colorectal Cancer
    • 6.3.4. Breast Cancer
    • 6.3.5. Prostate Cancer
    • 6.3.6. Others
  • 6.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.4.1. Solid
      • 6.4.1.1. Tablets
      • 6.4.1.2. Capsules
    • 6.4.2. Liquid
    • 6.4.3. Injectable
      • 6.4.3.1. Prefilled Syringes
      • 6.4.3.2. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
      • 6.6.1.1. By Drug Class
    • 6.6.2. Canada
      • 6.6.2.1. By Drug Class

7. Europe Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Cytotoxic Drugs
      • 7.1.1.1. Alkylating Agents
      • 7.1.1.2. Antimetabolites
      • 7.1.1.3. Others
    • 7.1.2. Targeted Drugs
      • 7.1.2.1. Monoclonal Antibodies
      • 7.1.2.2. Others
    • 7.1.3. Hormonal Drugs
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Therapy
    • 7.2.1. Chemotherapy
    • 7.2.2. Targeted Therapy
    • 7.2.3. Immunotherapy
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Lung Cancer
    • 7.3.2. Stomach Cancer
    • 7.3.3. Colorectal Cancer
    • 7.3.4. Breast Cancer
    • 7.3.5. Prostate Cancer
    • 7.3.6. Others
  • 7.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.4.1. Solid
      • 7.4.1.1. Tablets
      • 7.4.1.2. Capsules
    • 7.4.2. Liquid
    • 7.4.3. Injectable
      • 7.4.3.1. Prefilled Syringes
      • 7.4.3.2. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K
      • 7.6.1.1. By Drug Class
    • 7.6.2. Germany
      • 7.6.2.1. By Drug Class
    • 7.6.3. France
      • 7.6.3.1. By Drug Class
    • 7.6.4. Spain
      • 7.6.4.1. By Drug Class
    • 7.6.5. Italy
      • 7.6.5.1. By Drug Class
    • 7.6.6. Scandinavia
      • 7.6.6.1. By Drug Class
    • 7.6.7. Rest of Europe
      • 7.6.7.1. By Drug Class

8. Asia Pacific Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Cytotoxic Drugs
      • 8.1.1.1. Alkylating Agents
      • 8.1.1.2. Antimetabolites
      • 8.1.1.3. Others
    • 8.1.2. Targeted Drugs
      • 8.1.2.1. Monoclonal Antibodies
      • 8.1.2.2. Others
    • 8.1.3. Hormonal Drugs
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Therapy
    • 8.2.1. Chemotherapy
    • 8.2.2. Targeted Therapy
    • 8.2.3. Immunotherapy
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Lung Cancer
    • 8.3.2. Stomach Cancer
    • 8.3.3. Colorectal Cancer
    • 8.3.4. Breast Cancer
    • 8.3.5. Prostate Cancer
    • 8.3.6. Others
  • 8.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.4.1. Solid
      • 8.4.1.1. Tablets
      • 8.4.1.2. Capsules
    • 8.4.2. Liquid
    • 8.4.3. Injectable
      • 8.4.3.1. Prefilled Syringes
      • 8.4.3.2. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
      • 8.6.1.1. By Drug Class
    • 8.6.2. China
      • 8.6.2.1. By Drug Class
    • 8.6.3. India
      • 8.6.3.1. By Drug Class
    • 8.6.4. Australia
      • 8.6.4.1. By Drug Class
    • 8.6.5. Southeast Asia
      • 8.6.5.1. By Drug Class
    • 8.6.6. Rest of Asia Pacific
      • 8.6.6.1. By Drug Class

9. Latin America Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Cytotoxic Drugs
      • 9.1.1.1. Alkylating Agents
      • 9.1.1.2. Antimetabolites
      • 9.1.1.3. Others
    • 9.1.2. Targeted Drugs
      • 9.1.2.1. Monoclonal Antibodies
      • 9.1.2.2. Others
    • 9.1.3. Hormonal Drugs
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Therapy
    • 9.2.1. Chemotherapy
    • 9.2.2. Targeted Therapy
    • 9.2.3. Immunotherapy
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Lung Cancer
    • 9.3.2. Stomach Cancer
    • 9.3.3. Colorectal Cancer
    • 9.3.4. Breast Cancer
    • 9.3.5. Prostate Cancer
    • 9.3.6. Others
  • 9.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.4.1. Solid
      • 9.4.1.1. Tablets
      • 9.4.1.2. Capsules
    • 9.4.2. Liquid
    • 9.4.3. Injectable
      • 9.4.3.1. Prefilled Syringes
      • 9.4.3.2. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
      • 9.6.1.1. By Drug Class
    • 9.6.2. Mexico
      • 9.6.2.1. By Drug Class
    • 9.6.3. Rest of Latin America
      • 9.6.3.1. By Drug Class

10. Middle East & Africa Oncology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Cytotoxic Drugs
      • 10.1.1.1. Alkylating Agents
      • 10.1.1.2. Antimetabolites
      • 10.1.1.3. Others
    • 10.1.2. Targeted Drugs
      • 10.1.2.1. Monoclonal Antibodies
      • 10.1.2.2. Others
    • 10.1.3. Hormonal Drugs
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Therapy
    • 10.2.1. Chemotherapy
    • 10.2.2. Targeted Therapy
    • 10.2.3. Immunotherapy
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Lung Cancer
    • 10.3.2. Stomach Cancer
    • 10.3.3. Colorectal Cancer
    • 10.3.4. Breast Cancer
    • 10.3.5. Prostate Cancer
    • 10.3.6. Others
  • 10.4. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.4.1. Solid
      • 10.4.1.1. Tablets
      • 10.4.1.2. Capsules
    • 10.4.2. Liquid
    • 10.4.3. Injectable
      • 10.4.3.1. Prefilled Syringes
      • 10.4.3.2. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
      • 10.6.1.1. By Drug Class
    • 10.6.2. South Africa
      • 10.6.2.1. By Drug Class
    • 10.6.3. Rest of the Middle East & Africa
      • 10.6.3.1. By Drug Class

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. F. Hoffmann-La Roche Ltd.
    • 11.2.2. AbbVie, Inc.
    • 11.2.3. Novartis AG
    • 11.2.4. Pfizer Inc.
    • 11.2.5. AstraZeneca
    • 11.2.6. GSK plc
    • 11.2.7. Eli Lilly and Company
    • 11.2.8. Sanofi
    • 11.2.9. Bayer AG
    • 11.2.10. Merck & Co., Inc.
    • 11.2.11. Bristol-Myers Squibb Company

List of Tables

  • Table 1: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 3: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 4: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 5: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 6: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 7: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 8: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 9: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: Global Oncology Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 11: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 13: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 14: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 15: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 16: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 17: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 18: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 19: North America Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: North America Oncology Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 21: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 23: U.S. Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 24: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 25: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 26: Canada Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 27: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 29: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 30: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 31: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 32: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 33: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 34: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 35: Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Europe Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 38: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 39: U.K. Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 40: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 41: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 42: Germany Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 43: France Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 44: France Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 45: France Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 46: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 47: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 48: Italy Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 49: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 50: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 51: Spain Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 52: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 53: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 54: Scandinavia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 55: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 56: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 57: Rest of Europe Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 58: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 59: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 60: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 61: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 62: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 63: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 64: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 65: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 66: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 67: Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 68: China Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 69: China Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 70: China Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 71: India Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 72: India Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 73: India Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 74: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 75: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 76: Japan Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 77: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 78: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 79: Australia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 80: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 81: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 82: Southeast Asia Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 83: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 84: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 85: Rest of Asia Pacific Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 86: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 87: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 88: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 89: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 90: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 91: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 92: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 93: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 94: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 95: Latin America Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 96: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 97: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 98: Brazil Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 99: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 100: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 101: Mexico Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 102: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 103: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 104: Rest of Latin America Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 105: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 106: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 107: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 108: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 109: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 110: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Dosage Form, 2021-2034
  • Table 111: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Solid, 2021-2034
  • Table 112: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Injectable, 2021-2034
  • Table 113: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 114: Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 115: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 116: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 117: GCC Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 118: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 119: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 120: South Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034
  • Table 121: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 122: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Cytotoxic Drugs, 2021-2034
  • Table 123: Rest of Middle East & Africa Oncology Drugs Market Revenue (USD billion) Forecast, by Targeted Drugs, 2021-2034

List of Figures

  • Figure 1: Global Oncology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Oncology Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Oncology Drugs Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 4: Global Oncology Drugs Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Oncology Drugs Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 6: Global Oncology Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Oncology Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Oncology Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 11: North America Oncology Drugs Market Value Share (%), by Therapy, 2025
  • Figure 12: North America Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 13: North America Oncology Drugs Market Value Share (%), by Indication, 2025
  • Figure 14: North America Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 15: North America Oncology Drugs Market Value Share (%), by Dosage Form, 2025
  • Figure 16: North America Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Oncology Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Oncology Drugs Market Value Share (%), By Country, 2025
  • Figure 20: Europe Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Oncology Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 23: Europe Oncology Drugs Market Value Share (%), by Therapy, 2025
  • Figure 24: Europe Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 25: Europe Oncology Drugs Market Value Share (%), by Indication, 2025
  • Figure 26: Europe Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 27: Europe Oncology Drugs Market Value Share (%), by Dosage Form, 2025
  • Figure 28: Europe Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Oncology Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 35: Asia Pacific Oncology Drugs Market Value Share (%), by Therapy, 2025
  • Figure 36: Asia Pacific Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 37: Asia Pacific Oncology Drugs Market Value Share (%), by Indication, 2025
  • Figure 38: Asia Pacific Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 39: Asia Pacific Oncology Drugs Market Value Share (%), by Dosage Form, 2025
  • Figure 40: Asia Pacific Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Oncology Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 47: Latin America Oncology Drugs Market Value Share (%), by Therapy, 2025
  • Figure 48: Latin America Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 49: Latin America Oncology Drugs Market Value Share (%), by Indication, 2025
  • Figure 50: Latin America Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 51: Latin America Oncology Drugs Market Value Share (%), by Dosage Form, 2025
  • Figure 52: Latin America Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Oncology Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Oncology Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Oncology Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 59: Middle East & Africa Oncology Drugs Market Value Share (%), by Therapy, 2025
  • Figure 60: Middle East & Africa Oncology Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 61: Middle East & Africa Oncology Drugs Market Value Share (%), by Indication, 2025
  • Figure 62: Middle East & Africa Oncology Drugs Market Value (USD billion), by Dosage Form, 2025 & 2034
  • Figure 63: Middle East & Africa Oncology Drugs Market Value Share (%), by Dosage Form, 2025
  • Figure 64: Middle East & Africa Oncology Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Oncology Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Oncology Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Oncology Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Oncology Drugs Market Share (%), By Company, 2025